Rijnders, Maud http://orcid.org/0000-0002-1552-0813
Robbrecht, Debbie G. J.
Oostvogels, Astrid A. M.
van Brakel, Mandy
Boormans, Joost L.
Aarts, Maureen J. B.
Balcioglu, Hayri E.
Hamberg, Paul
Voortman, Jens
Westgeest, Hans M.
Lolkema, Martijn P.
de Wit, Ronald
van der Veldt, Astrid A. M.
Debets, Reno
Funding for this research was provided by:
Merck Sharp and Dohme
Article History
Received: 8 October 2021
Accepted: 27 June 2022
First Online: 17 August 2022
Declarations
:
: Debbie G.J. Robbrecht has received consultancy fees from Bayer, Cantargia, Servier, Faron Pharmaceuticals, and Merck, and travel expenses from Sanofi. Maureen J.B. Aarts has received consultancy fees from BMS, Merck, Ipsen, Novartis, Pfizer, Pierre Fabre, Sanofi, and Astellas, and has received a research grant (paid to the institute) from Pfizer. Joost L. Boormans has received consultancy fees from MSD, BMS, Janssen, Eight Medical, Ambu, and Ismar Healthcare, and research grants (paid to the institute) from Decipher Biosciences. Paul Hamberg has received consultancy fees from Merck, Astellas, ipsen, Astra Zeneca, BMS, and Pfizer. Martijn P. Lolkema has received consultancy fees from Sanofi, Janssen, Astellas, Incyte, Amgen, Bayer, Servier and Pfizer, and has received research grants (paid to the institute) from Sanofi, Janssen, Merck, and Astellas. Jens Voortman has received consultancy fees from Roche and Merck, and travel fees from Sanofi, Pfizer, Merck, TEVA, Astellas, Ipsen, and Pfizer. Hans M. Westgeest has received consultancy fees from Astellas and Roche, and travel expenses from Ipsen and Astellas. Ronald de Wit has received consultancy fees from Sanofi, Merck, Bayer, Janssen, Roche, Clovis, and Astellas, speaker fees from Sanofi and Merck, and has received research grants (paid to the institute) from Sanofi and Bayer. Astrid A.M. van der Veldt has received consultancy fees (paid to the institute) from BMS, Merck, Pfizer, Novartis, Roche, Eisai, Ipsen, Pierre Fabre, and Sanofi, and travel expenses from Bayer. Reno Debets has received consultancy fees and travel expenses from Genticel and Bluebird bio, and research grants (paid to the institute) from Merck. Maud Rijnders, Astrid A.M. Oostvogels, Mandy van Brakel, and Hayri E. Balcioglu have declared no conflict of interest.
: Patients with advanced or metastatic UC were included in a phase II prospective biomarker discovery study (RESPONDER trial, NCT03263039). The study protocol was approved by the medical ethics review board of the Foundation BEBO (Evaluation of Ethics in Biomedical Research), Assen, The Netherlands, and complies with all relevant national and institutional ethical regulations. All patients provided written informed consent before inclusion in the study.
: All authors listed on the title page have made substantial contributions, have read the manuscript, attest to the validity and legitimacy of the data and its interpretation, and agree to its publication.